Millendo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.millendo.com
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Phase 2
Completed
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Drug: ATR-101
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Millendo Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02804178
- Locations
- 🇺🇸
Mayo Clinic - Rochester, Rochester, Minnesota, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Phase 1
Completed
- Conditions
- Adrenal CancerACCAdrenocortical Carcinoma
- Interventions
- Drug: ATR-101
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Millendo Therapeutics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT01898715
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
🇺🇸National Institutes of Health/National Cancer Institute, Bethesda, Maryland, United States
🇺🇸MDAnderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath